Clinical perspectives in using CA 125

Contemporary Ob-Gyn

Volumn 41, Issue 2, 1996, Pages 99-118

  Knapp, Robert C ^a   Jacobs, Ian ^b   Schwartz, Peter E ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 6244288677     PISSN: 00903159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Bast RC Jr, Feeney M, Lazarus H, et al: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331
2. Bast RC Jr, Klug TL, St John E, et al: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883
3. O'Brien TJ, Raymond LM, Bannon GA, et al: New monoclonal antibodies identify the glycoprotein carrying the CA 125 epitope. Am J Obstet Gynecol 1991;165:1857
4. Kenemans P. van Kamp GJ, Oehr P, et al: Heterologous double-determinant immunoradiometric assay CA 125II: Reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem 1993;39:2509
5. Malkasian GD Jr, Knapp RC, Lavin FT, et al: Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: Discrimination of benign from malignant disease. Am J Obstet Gynecol 1988;159:341
6. Schwartz PE: The role of CA 125 in the evaluation of palpable or enlarged postmenopausal ovaries. Am J Obstet Gynecol 1988;158:1072
7. Jacobs I, Oram D, Fairbanks J, et al: A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Er J Obstet Gynecol 1990;97:922
8. NIH Consensus Conference, Ovarian Cancer. Screening, treatment, and follow-up. JAMA 1995;273:491
9. Cancer of the ovary. ACOG Technical Bulletin. Number 141, May, 1990
10. Lavin PT, Knapp RC, Malkasian G, et al: CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol 1987;69:223
11. van der Burg MEL: Tumor marker CA 125: The clinical significance of the serum marker CA 125 in the management of patients with ovarian cancer (Doctoral thesis). Dordrecht, The Netherlands, ICG Printing, 1989
12. Rustin GJS, Nelstrap A, Stilwel J, et al: Savings obtained by CA 125 measurements during therapy for ovarian carcinoma. Eur J Cancer 1992;28:79
13. Jacobs I, Bast RC Jr.: The CA 125 tumor-associated antigen: A review of the literature. Hum Reprod 1989;4:1
14. Brand E. Lidor Y: The decline of CA 125 level after surgery reflects the size of residual ovarian cancer. Obstet Gynecol 1993;81:29
15. Cruickshank DJ, Paul J, Lewis CR, et al: An independent evaluation of the potential clinical usefulness of proposed CA 125 indices previously shown to be of prognostic significance in epithelial ovarian cancer. Br J Cancer 1992;65:597
16. Liu P, Alberts DS, Federico M, et al: CA 125 concentration 8 weeks after treatment initiation independently predicts survival in patients with advanced epithelial ovarian cancer: A Southwest Oncology Group (SWOG). Pro Am Soc Cl Oncol 1995;14:266
17. Mobus V, Kreienberg R, Crombach G, et al: Evaluation of CA 125 as a prognostic and predictive factor in ovarian cancer. J Tumor Marker Oncol 1988;3:251
18. van der Burg MEL, Lammes FB, van Putten WLJ, et al: Ovarian cancer: The prognostic value of the serum half-life of CA 125 during induction chemotherapy. Gynecol Oncol 1988;30:307
19. Berek JS, Knapp RC, Malkasian GD, et al: CA 125 serum levels correlated with second-look operations among ovarian cancer patients. Obstet Gynecol 1986;67:685
20. Niloff JM, Knapp RC, Lavin PT, et al: The CA 125 assay as a predictor of clinical recurrence in epitnelial ovarian cancer. Am J Obstet Gynecol 1986;155:56
21. Finkler NJ, Kapnick SJ, Griffiths CT, et al: Elevated CA 125 serum levels and epithelial ovarian cancer metastatic to retroperitoneal lymph nodes. Gynecol Oncol 1988;29:356
22. Young RC, Walton LA, Ellenber SS, et al: Adjuvant therapy in stage I and Stage II epithelial ovarian cancer. N Engl J Med 1990;322:1070
23. Piver MS, Fanning J, Craig KA: Ovarian cancer, in Knapp RC, Berkowitz RS (eds): Gynecologic Oncology, 2nd ed. McGraw Hill, New York, N.Y., 1993, p 253
24. Skates SJ, Feng-Ji X, Yin-Hua Y, et al: Towards an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 1995;76:2004
25. McGarrity KA, Pettersson F, Ulfelder H (eds): The annual report on the results of the treatment of gynecological cancer. Stockholm, Radiumhemmet, 1982
26. Bates SE: Clinical application of serum tumor markers. Ann Intern Med 1991;115:623
27. Zurawski VR Jr, Orjaseter H, Andersen A, et al: Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: Relevance for early detection of ovarian cancer. Int J Cancer 1988;42:677
28. Einhorn N, Sjovall K, Knapp RC, et al: Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 1992;80:14
29. Jacobs I, Davies AP, Bridges J, et al: Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. Brit Med J 1993;306:1030